Safety and Efficacy of Spray Intranasal Live Attenuated Influenza Vaccine: Systematic Review and Meta-Analysis
Giulia Perego,
Giacomo Pietro Vigezzi,
Giulia Cocciolo,
Federica Chiappa,
Stefano Salvati,
Federica Balzarini,
Anna Odone,
Carlo Signorelli,
Vincenza Gianfredi
Affiliations
Giulia Perego
School of Medicine, Vita-Salute San Raffaele University, Via Olgettina, 58, 20132 Milan, Italy
Giacomo Pietro Vigezzi
School of Medicine, Vita-Salute San Raffaele University, Via Olgettina, 58, 20132 Milan, Italy
Giulia Cocciolo
School of Medicine, Vita-Salute San Raffaele University, Via Olgettina, 58, 20132 Milan, Italy
Federica Chiappa
School of Medicine, Vita-Salute San Raffaele University, Via Olgettina, 58, 20132 Milan, Italy
Stefano Salvati
School of Medicine, Vita-Salute San Raffaele University, Via Olgettina, 58, 20132 Milan, Italy
Federica Balzarini
Dipartimento per la Programmazione, Accreditamento, Acquisto delle Prestazioni Sanitarie e Sociosanitarie (PAAPSS), Servizio Autorizzazione e Accreditamento, Agenzia di Tutela della Salute (ATS) di Bergamo, Via Galliccioli, 4, 24121 Bergamo, Italy
Anna Odone
Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 27100 Pavia, Italy
Carlo Signorelli
School of Medicine, Vita-Salute San Raffaele University, Via Olgettina, 58, 20132 Milan, Italy
Vincenza Gianfredi
School of Medicine, Vita-Salute San Raffaele University, Via Olgettina, 58, 20132 Milan, Italy
Although influenza is a major public health concern, little is known about the use of spray live attenuated influenza vaccine (LAIV) among adults. For this reason, we conducted a systematic review and meta-analysis to investigate the efficacy and safety of LAIV, especially in adults with/without clinical conditions and children p-value = 0.022; based on 488 participants, without heterogeneity (I2 = 0.0%)). The meta-analysis also confirmed no significant association with systemic adverse events. Only rhinorrhea, nasal congestion, and sore throat were significantly associated with LAIV compared to the placebo. Despite limited available evidence, LAIV has proved to be a safe and effective flu vaccination, also due to its very low invasiveness, and our review’s results can be considered a starting point for guiding future research and shaping forthcoming vaccination campaigns.
